Modulating T regulatory cells in cancer: how close are we?

Ashish Banerjee, Ajithkumar Vasanthakumar, George Grigoriadis

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Regulatory T cells (Tregs) are a specialized subset of CD4 T cells that have an indispensable role in maintaining immune homeostasis and tolerance. Although studies in mice and humans have clearly highlighted that the absence of these cells results in severe autoimmunity and inflammation, increased Treg numbers and/or function is not always beneficial. This is best exemplified in certain cancers where increased Tregs promote cancer progression by interfering with immune surveillance. Conversely, in other types of cancers that have an inflammatory component, Tregs can inhibit cancer progression by dampening inflammation. In this review article, we provide a historical perspective of the discovery of Tregs, followed by a summary of the existing literature on the role of Tregs in malignancy.
Original languageEnglish
Pages (from-to)340 - 349
Number of pages10
JournalImmunology and Cell Biology
Volume91
Issue number5
DOIs
Publication statusPublished - 2013

Cite this

@article{e7640f9a1f994d049fca932f968b1adb,
title = "Modulating T regulatory cells in cancer: how close are we?",
abstract = "Regulatory T cells (Tregs) are a specialized subset of CD4 T cells that have an indispensable role in maintaining immune homeostasis and tolerance. Although studies in mice and humans have clearly highlighted that the absence of these cells results in severe autoimmunity and inflammation, increased Treg numbers and/or function is not always beneficial. This is best exemplified in certain cancers where increased Tregs promote cancer progression by interfering with immune surveillance. Conversely, in other types of cancers that have an inflammatory component, Tregs can inhibit cancer progression by dampening inflammation. In this review article, we provide a historical perspective of the discovery of Tregs, followed by a summary of the existing literature on the role of Tregs in malignancy.",
author = "Ashish Banerjee and Ajithkumar Vasanthakumar and George Grigoriadis",
year = "2013",
doi = "10.1038/icb.2013.12",
language = "English",
volume = "91",
pages = "340 -- 349",
journal = "Immunology and Cell Biology",
issn = "0818-9641",
publisher = "Nature Publishing Group",
number = "5",

}

Modulating T regulatory cells in cancer: how close are we? / Banerjee, Ashish; Vasanthakumar, Ajithkumar; Grigoriadis, George.

In: Immunology and Cell Biology, Vol. 91, No. 5, 2013, p. 340 - 349.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Modulating T regulatory cells in cancer: how close are we?

AU - Banerjee, Ashish

AU - Vasanthakumar, Ajithkumar

AU - Grigoriadis, George

PY - 2013

Y1 - 2013

N2 - Regulatory T cells (Tregs) are a specialized subset of CD4 T cells that have an indispensable role in maintaining immune homeostasis and tolerance. Although studies in mice and humans have clearly highlighted that the absence of these cells results in severe autoimmunity and inflammation, increased Treg numbers and/or function is not always beneficial. This is best exemplified in certain cancers where increased Tregs promote cancer progression by interfering with immune surveillance. Conversely, in other types of cancers that have an inflammatory component, Tregs can inhibit cancer progression by dampening inflammation. In this review article, we provide a historical perspective of the discovery of Tregs, followed by a summary of the existing literature on the role of Tregs in malignancy.

AB - Regulatory T cells (Tregs) are a specialized subset of CD4 T cells that have an indispensable role in maintaining immune homeostasis and tolerance. Although studies in mice and humans have clearly highlighted that the absence of these cells results in severe autoimmunity and inflammation, increased Treg numbers and/or function is not always beneficial. This is best exemplified in certain cancers where increased Tregs promote cancer progression by interfering with immune surveillance. Conversely, in other types of cancers that have an inflammatory component, Tregs can inhibit cancer progression by dampening inflammation. In this review article, we provide a historical perspective of the discovery of Tregs, followed by a summary of the existing literature on the role of Tregs in malignancy.

UR - http://www.ncbi.nlm.nih.gov/pubmed/23567897

U2 - 10.1038/icb.2013.12

DO - 10.1038/icb.2013.12

M3 - Article

VL - 91

SP - 340

EP - 349

JO - Immunology and Cell Biology

JF - Immunology and Cell Biology

SN - 0818-9641

IS - 5

ER -